EUVIMEDEUVIMED entdecken
Multizentrische Studie

Nationwide Insights on Immunotherapy in a Low- and Middle-Income Country: Armenia's Struggle for Equitable Cancer Care in an Out-of-Pocket System

Amalya Sargsyan iD, Gevorg Tamamyan iD, Arman Oganisian iD, Davit Zohrabyan, Liana Safaryan, Armen Avagyan, Lilit Harutyunayn iD, Mariam Sargsyan, Martin Harutyunyan, Nune Karapetyan, Naira Janoyan, Levon Badalyan und 10 weitere

JCO Global Oncology · 2025

DOI: 10.1200/go-25-00040 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Amalya Sargsyan und 21 weiteren Autor:innen. Beteiligte Einrichtung: Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE In Armenia, a lower-middle-income country, cancer causes 21% of all deaths, with over half of cases diagnosed at advanced stages. Without universal health insurance, patients rely on out-of-pocket payments or black-market channels for costly immunotherapies, underscoring the need for real-world data to inform equitable policy reforms. METHODS We conducted a multicenter, retrospective cohort study of patients who received at least one dose of an immune checkpoint inhibitor (ICI) between January 2017 and December 2023 across six Armenian oncology centers. Eligible patients had histologically confirmed malignancy and ≥6 months of follow-up. Demographic, clinical, biomarker, and treatment data were extracted from records. Overall survival (OS) was estimated by the Kaplan-Meier method; log-rank tests and Cox models evaluated associations. A 6-month landmark analysis adjusted for immortal time bias. RESULTS Of the 585 patients screened, 373 met inclusion criteria (67% male; median age, 61 years); 68% had stage IV disease. The median OS was 31 months. Liver metastases predicted poorer survival (19 v 26 months, P = .027). Nonsmokers had better OS than smokers (31 v 24 months, P = .019). High PD-L1 expression (≥50%) was associated with improved OS (40 v 16 months, P = .025). Receiving >6 ICI cycles conferred longer OS (45 v 23 months, P < .001), although not significant in landmark analysis ( P = .64). Financial hardship and disease progression were key reasons for early discontinuation. CONCLUSION Immunotherapy shows promise in Armenia despite financial barriers. Drawing on models from India and China, pooled procurement, negotiated pricing, and partial reimbursement, Armenia could expand biomarker testing, reduce drug costs, and implement tiered insurance. These steps are vital to optimize access and outcomes in this resource-limited setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsImmune Checkpoint InhibitorsHumansArmeniaMaleFemaleMiddle AgedRetrospective StudiesAgedHealth ExpendituresAdultDeveloping Countries

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Yeolyan Hematology and Oncology Center, Yerevan, Armenia.
  • Immune Oncology Research Institute, Yerevan, Armenia.
  • Yerevan State Medical University, Yerevan, Armenia.
  • Brown University, Providence, RI.
  • Mikaelyan Institute of Surgery, Yerevan, Armenia.
  • National Center of Oncology, Yerevan, Armenia.

ORCID-Profile: Amalya Sargsyan, Gevorg Tamamyan, Arman Oganisian, Lilit Harutyunayn, Mariam Mailian, Vardan Bardakhchyan, Elen Baloyan, Karen Bedirian, Shushan Hovsepyan, Samvel Bardakhchyan

Zitieren

APA

Sargsyan, A., Tamamyan, G., Oganisian, A., Zohrabyan, D., Safaryan, L., Avagyan, A., Harutyunayn, L., Sargsyan, M., Harutyunyan, M., Karapetyan, N., Janoyan, N., Badalyan, L., Mailian, M., Geokchyan, H., Bardakhchyan, V., Baloyan, E., Petrosyan, H., Soghomonyan, K., Tadevosyan, A., …, & Bardakhchyan, S. (2025). Nationwide Insights on Immunotherapy in a Low- and Middle-Income Country: Armenia's Struggle for Equitable Cancer Care in an Out-of-Pocket System. JCO Global Oncology. https://doi.org/10.1200/go-25-00040

Vancouver

Sargsyan A, Tamamyan G, Oganisian A, Zohrabyan D, Safaryan L, Avagyan A, et al. Nationwide Insights on Immunotherapy in a Low- and Middle-Income Country: Armenia's Struggle for Equitable Cancer Care in an Out-of-Pocket System. JCO Global Oncology. 2025. doi:10.1200/go-25-00040

BibTeX
@article{Sargsyan2025,
  author = {Sargsyan, Amalya and Tamamyan, Gevorg and Oganisian, Arman and Zohrabyan, Davit and Safaryan, Liana and Avagyan, Armen and Harutyunayn, Lilit and Sargsyan, Mariam and Harutyunyan, Martin and Karapetyan, Nune and Janoyan, Naira and Badalyan, Levon and Mailian, Mariam and Geokchyan, Haykuhi and Bardakhchyan, Vardan and Baloyan, Elen and Petrosyan, Hasmik and Soghomonyan, Karine and Tadevosyan, Anna and Bedirian, Karen and Hovsepyan, Shushan and Bardakhchyan, Samvel},
  title = {Nationwide Insights on Immunotherapy in a Low- and Middle-Income Country: Armenia's Struggle for Equitable Cancer Care in an Out-of-Pocket System},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-25-00040}
}
Kostenlos starten →